TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1580842

Group type: EXPERIMENTAL
Intervention: Tarsal rotation for minor trichiasis
Number of subjects: 384

Group type: COMPARATOR
Intervention: Electrolysis for minor trichiasis
Number of subjects: 384

Group type: COMPARATOR
Intervention: Cryoablation for minor trichiasis
Number of subjects: 384

Group type: EXPERIMENTAL
Intervention: Tarsal rotation for major trichiasis
Number of subjects: 384

Group type: COMPARATOR
Intervention: Tarsal advance and rotation for major trichiasis
Number of subjects: 384

Group type: EXPERIMENTAL
Intervention: Surgery for major trichiasis
Number of subjects: 384
Study: 6421243

Group type: EXPERIMENTAL
Intervention: Group A: mitomycin C (MMC) + 5‐fluorouracil (5‐FU)
Number of subjects: 848

Group type: EXPERIMENTAL
Intervention: Group B: MMC + 5‐FU + PSK or MMC + 5‐FU + OK‐432
Number of subjects: 848

Group type: COMPARATOR
Intervention: Group C: surgery alone
Number of subjects: 848

Group type: EXPERIMENTAL
Intervention: Adjuvant immunochemotherapy using OK‐432
Number of subjects: 848
Study: 3549316

Group type: EXPERIMENTAL
Intervention: GP 47680 and GP 47779 (carbamazepine analogues)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Carbamazepine
Number of subjects: 24
Study: 31218418

Group type: EXPERIMENTAL
Intervention: Two-field lymph node dissection (2F group)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Three-field lymph node dissection (3F group)
Number of subjects: 31
Study: 29251456

Group type: EXPERIMENTAL
Intervention: 10% carbamide peroxide 1 hour a day
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 10% carbamide peroxide overnight
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 7.5% hydrogen peroxide 1 hour a day
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 7.5% hydrogen peroxide overnight
Number of subjects: 80
Study: 26152626

Group type: EXPERIMENTAL
Intervention: Daycare laparoscopic cholecystectomy
Number of subjects: 62

Group type: COMPARATOR
Intervention: Overnight stay laparoscopic cholecystectomy
Number of subjects: 62
Study: 24461612

Group type: EXPERIMENTAL
Intervention: Haloperidol 2.5 mg intravenously every 8 h
Number of subjects: 142

Group type: COMPARATOR
Intervention: Placebo (0.9% saline) intravenously every 8 h
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 142

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 142
Study: 21646549

Group type: EXPERIMENTAL
Intervention: Self-affirmation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Stereotype threat
Number of subjects: 0
Study: 18363424

Group type: EXPERIMENTAL
Intervention: Family therapy + pharmacotherapy
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Multi-family psychoeducational group + pharmacotherapy
Number of subjects: 92

Group type: COMPARATOR
Intervention: Pharmacotherapy alone
Number of subjects: 92
Study: 16931506

Group type: EXPERIMENTAL
Intervention: Abnormal SMN1 gene copy numbers (one or three copies)
Number of subjects: 600

Group type: COMPARATOR
Intervention: SMN2 gene copy numbers
Number of subjects: 600
Study: 12760983

Group type: EXPERIMENTAL
Intervention: Magnesium sulfate (0.25 mmol/kg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 40
Study: 11061730

Group type: EXPERIMENTAL
Intervention: Intensive geriatric rehabilitation (n=120)
Number of subjects: 243

Group type: COMPARATOR
Intervention: Control group (n=123)
Number of subjects: 243
Study: 9177961

Group type: EXPERIMENTAL
Intervention: Five-day treatment with cefprozil
Number of subjects: 708

Group type: EXPERIMENTAL
Intervention: Ten-day treatment with cefprozil
Number of subjects: 708

Group type: EXPERIMENTAL
Intervention: Ten-day treatment with cefprozil (in patients with three or more previous episodes)
Number of subjects: 708

Group type: EXPERIMENTAL
Intervention: Five-day treatment with cefprozil (in patients with three or more previous episodes)
Number of subjects: 708
Study: 7505351

Group type: EXPERIMENTAL
Intervention: Amlodipine (AM) 5 mg, adjusted to 10 mg if necessary
Number of subjects: 32

Group type: COMPARATOR
Intervention: Nitrendipine (NTR) 10 mg, adjusted to 20 mg if necessary
Number of subjects: 32
Study: 3100466

Group type: EXPERIMENTAL
Intervention: Stanozolol (10 mg/day)
Number of subjects: 10
Study: 29108873

Group type: EXPERIMENTAL
Intervention: Pilates (N = 14)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Conventional therapeutic exercise (CTE) (N = 14)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control (N = 13)
Number of subjects: 41
Study: 27026642

Group type: EXPERIMENTAL
Intervention: 20 mg of prednisone orally followed by 2 doses of intravenous hydrocortisone, each 8 hours apart
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 25049134

Group type: EXPERIMENTAL
Intervention: Exendin‐[9‐39] (Ex‐9) infusion (600‐750 pmol/kg/min)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo (saline) infusion
Number of subjects: 8
Study: 22554716

Group type: EXPERIMENTAL
Intervention: RP103 (delayed-release cysteamine bitartrate) taken every 12 hours
Number of subjects: 43

Group type: COMPARATOR
Intervention: Cystagon (immediate-release cysteamine bitartrate) taken every 6 hours
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: RP103 (delayed-release cysteamine bitartrate)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Cystagon (immediate-release cysteamine bitartrate)
Number of subjects: 43
Study: 20636550

Group type: EXPERIMENTAL
Intervention: Nanocrystalline silver dressing
Number of subjects: 281

Group type: COMPARATOR
Intervention: Cadexomer iodine dressing
Number of subjects: 281
Study: 18302069

Group type: EXPERIMENTAL
Intervention: Gum chewing (three times a day from the first postoperative morning until oral intake)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (no gum chewing)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Gum chewing and Control group
Number of subjects: 18
Study: 15986959

Group type: EXPERIMENTAL
Intervention: Ethanol-based one-bottle adhesive system (Gluma Comfort Bond) applied to dry dentin (Group 1)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Acetone-based one-bottle adhesive system (Gluma One Bond) applied to dry dentin (Group 2)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Ethanol-based one-bottle adhesive system (Gluma Comfort Bond) applied to moist dentin (Group 3)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Acetone-based one-bottle adhesive system (Gluma One Bond) applied to moist dentin (Group 4)
Number of subjects: 16
Study: 14970004

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) infusion
Number of subjects: 12
Study: 10473874

Group type: EXPERIMENTAL
Intervention: GPIIb/IIIa inhibitors
Number of subjects: 20000
Study: 7593106

Group type: EXPERIMENTAL
Intervention: Repair of a ruptured deltoid ligament
Number of subjects: 50

Group type: COMPARATOR
Intervention: No repair of a ruptured deltoid ligament (control)
Number of subjects: 50
Study: 2273204

Group type: EXPERIMENTAL
Intervention: Estrogen/progesterone therapy
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 24
Study: 7375871

Group type: EXPERIMENTAL
Intervention: Indomethacin 25 mg t.i.d. for 3 weeks
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Indomethacin 25 mg t.i.d. plus 100 mg suppository at night after 5-day placebo
Number of subjects: 21

Group type: COMPARATOR
Intervention: Single oral dose of 50 mg indomethacin
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Indomethacin 25 mg q.i.d. for 8 days
Number of subjects: 21
Study: 30004624

Group type: EXPERIMENTAL
Intervention: Intraoperative remifentanil infusion followed by remifentanil maintenance during the recovery phase (0.05 μg/kg/min)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Intraoperative remifentanil infusion (0.2 μg/kg/min) discontinued upon surgery completion
Number of subjects: 80
Study: 26869078

Group type: EXPERIMENTAL
Intervention: ProDisc-C total disc arthroplasty (TDA)
Number of subjects: 63

Group type: COMPARATOR
Intervention: ACDF
Number of subjects: 63
Study: 24928632

Group type: EXPERIMENTAL
Intervention: Modified Story Memory Technique (memory rehabilitation protocol)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 23226263

Group type: EXPERIMENTAL
Intervention: Active hypoxic exposure (AHE) (plus exercise)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Passive hypoxic exposure (PHE)
Number of subjects: 20
Study: 20846199

Group type: EXPERIMENTAL
Intervention: Orally disintegrating olanzapine (ODO)
Number of subjects: 149

Group type: COMPARATOR
Intervention: Standard olanzapine tablets (SOT)
Number of subjects: 149
Study: 17427827

Group type: EXPERIMENTAL
Intervention: 9.5% HF for 30 seconds
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: 300 mJ laser etching
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: 600 mJ laser etching
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: 900 mJ laser etching
Number of subjects: 110

Group type: COMPARATOR
Intervention: Control (untreated specimens)
Number of subjects: 110
Study: 15732859

Group type: EXPERIMENTAL
Intervention: 0.454% stannous fluoride/sodium hexametaphosphate dentifrice
Number of subjects: 199

Group type: COMPARATOR
Intervention: 0.30% triclosan/2.0% Gantrez copolymer dentifrice
Number of subjects: 199
Study: 12199627

Group type: COMPARATOR
Intervention: IFL combination (fluorouracil [5‐FU], leucovorin, and irinotecan [CPT‐11, Camptosar])
Number of subjects: 0

Group type: COMPARATOR
Intervention: IFL with bevacizumab (Avastin)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 5‐FU and leucovorin with SU5416
Number of subjects: 0

Group type: COMPARATOR
Intervention: SU5416 combined with IFL
Number of subjects: 0
Study: 9569999

Group type: EXPERIMENTAL
Intervention: Non-steroidal anti-inflammatory drugs (NSAIDs) including aspirin, diclofenac, naproxen, indomethacin, and ibuprofen
Number of subjects: 0
Study: 7734469

Group type: EXPERIMENTAL
Intervention: Desipramine
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Carbamazepine
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study: 3195729

Group type: COMPARATOR
Intervention: 3 mg EM without bupivacaine
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: 3 mg EM with 0.125% bupivacaine
Number of subjects: 150

Group type: COMPARATOR
Intervention: 5 mg EM without bupivacaine
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: 5 mg EM with 0.125% bupivacaine
Number of subjects: 150
Study: 30314508

Group type: EXPERIMENTAL
Intervention: YWF
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: YWF + gypsum
Number of subjects: 72

Group type: COMPARATOR
Intervention: Allopurinol
Number of subjects: 72
Study: 27172582

Group type: EXPERIMENTAL
Intervention: Personalized normative feedback (PNF)
Number of subjects: 252

Group type: COMPARATOR
Intervention: Assessment only (Control)
Number of subjects: 252
Study: 24978955

Group type: EXPERIMENTAL
Intervention: Vilazodone
Number of subjects: 863

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 863
Study: 23227695

Group type: EXPERIMENTAL
Intervention: Shu-needle therapy combined with ozone injection of low concentration
Number of subjects: 130

Group type: COMPARATOR
Intervention: Conventional acupotomy therapy combined with ozone injection of low concentration
Number of subjects: 130
Study: 20977758

Group type: EXPERIMENTAL
Intervention: Percutaneous Coronary Intervention (PCI)
Number of subjects: 611

Group type: EXPERIMENTAL
Intervention: Coronary Artery Bypass Grafting (CABG)
Number of subjects: 611

Group type: EXPERIMENTAL
Intervention: Medical Treatment (MT)
Number of subjects: 611
Study: 19036146

Group type: EXPERIMENTAL
Intervention: Transarterial chemoembolization plus sorafenib 400 mg bid
Number of subjects: 208

Group type: COMPARATOR
Intervention: Transarterial chemoembolization plus placebo
Number of subjects: 208
Study: 16096175

Group type: EXPERIMENTAL
Intervention: Transdermal HRT (Estalis)
Number of subjects: 202

Group type: COMPARATOR
Intervention: Oral HRT (Kliogest)
Number of subjects: 202
Study: 12171880

Group type: EXPERIMENTAL
Intervention: ISIS 3521
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: ISIS 5132
Number of subjects: 31
Study: 9189964

Group type: EXPERIMENTAL
Intervention: 6% middle molecular weight hydroxyethyl starch (HES)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 6% dextran 60 (DEX)
Number of subjects: 16
Study: 1975188

Group type: EXPERIMENTAL
Intervention: Esmolol 50 mg
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Esmolol 100 mg
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 7018482

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Pindolol
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 18

Group type: COMPARATOR
Intervention: Chlorothiazide (control)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: All beta adrenoreceptor-blocking drugs
Number of subjects: 18
Study: 31128959

Group type: EXPERIMENTAL
Intervention: Interactive Decision Aid (DA)
Number of subjects: 570

Group type: COMPARATOR
Intervention: Non-Interactive Decision Aid (DA)
Number of subjects: 570

Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 570

Group type: EXPERIMENTAL
Intervention: Both Interactive and Non-Interactive DAs
Number of subjects: 570
Study: 28935463

Group type: EXPERIMENTAL
Intervention: Image fusion (IF) guidance in TAVI
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (no image fusion)
Number of subjects: 31
Study: 25222574

Group type: EXPERIMENTAL
Intervention: Intra-articular magnesium sulphate (100 mg/mL, 10 mL)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Normal saline (10 mL)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Intra-articular magnesium sulphate
Number of subjects: 67
Study: 24800921

Group type: EXPERIMENTAL
Intervention: 4 mg/kg sugammadex
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: 16 mg/kg sugammadex
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo with enoxaparin
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo with UFH
Number of subjects: 56
Study: 22898574

Group type: EXPERIMENTAL
Intervention: Wii training (Nintendo Wii Sports™ and Nintendo Wii Fit™) for 10 weeks, 2 sessions per week
Number of subjects: 40
Study: 20029520

Group type: EXPERIMENTAL
Intervention: LOW+GLU (6.4% glucose solution)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: LOW+PLA (placebo solution)
Number of subjects: 3

Group type: COMPARATOR
Intervention: NORM (no beverage during training)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 3
Study: 17304006

Group type: EXPERIMENTAL
Intervention: Moderate intensity exercise (58.4 ± 1.3% of VO2max) for 60 minutes
Number of subjects: 15

Group type: COMPARATOR
Intervention: Non-exercising control
Number of subjects: 15
Study: 15522005

Group type: EXPERIMENTAL
Intervention: Rifaximin treatment for 3 days
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Rifaximin treatment
Number of subjects: 27
Study: 11549996

Group type: EXPERIMENTAL
Intervention: Amnioinfusion
Number of subjects: 206

Group type: COMPARATOR
Intervention: No amnioinfusion (control)
Number of subjects: 206
Study: 10328567

Group type: EXPERIMENTAL
Intervention: Intranasal diazepam (2 mg)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Intravenous diazepam (2 mg)
Number of subjects: 9
Study: 8529334

Group type: EXPERIMENTAL
Intervention: Caffeine (2 mg/kg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Caffeine (4 mg/kg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Paraxanthine (2 mg/kg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Paraxanthine (4 mg/kg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 2366601

Group type: EXPERIMENTAL
Intervention: Cognitive impairment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of cognitive impairment and functional impairment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Demographic characteristics (whites, nonhomeowners, living alone, prior nursing home stays)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Older persons who were unmarried, had a low income, had no assets, and those on Medicaid
Number of subjects: 0
Study: 637293

Group type: EXPERIMENTAL
Intervention: Two vial formulation of etomidate (30 mg etomidate sulphate in 20 ml phosphate buffered solution)
Number of subjects: 209

Group type: COMPARATOR
Intervention: New formulation of etomidate (5ml ampoules containing 2% etomidate base in polyethylene glycol 1000)
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Two vial formulation of etomidate
Number of subjects: 209

Group type: COMPARATOR
Intervention: New formulation of etomidate
Number of subjects: 209
Study: 31596411

Group type: EXPERIMENTAL
Intervention: Infant stimulation therapy (auditory, tactile, visual and vestibular)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 120
Study: 28706334

Group type: EXPERIMENTAL
Intervention: Demonstration of MDI technique (Group A)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Pictorial leaflet for MDI technique (Group B)
Number of subjects: 100
Study: 26460564

Group type: EXPERIMENTAL
Intervention: Cetrorelix (5mg days 1-2; 3mg days 3-5)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Cetrorelix
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study: 24163868

Group type: EXPERIMENTAL
Intervention: Thermal welding (TW) tonsillectomy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Cold dissection (CD) tonsillectomy
Number of subjects: 60
Study: 20390342

Group type: EXPERIMENTAL
Intervention: High CTEN expression
Number of subjects: 1409

Group type: EXPERIMENTAL
Intervention: CTEN expression
Number of subjects: 1409

Group type: EXPERIMENTAL
Intervention: Increased CTEN expression
Number of subjects: 1409
Study: 19641483

Group type: EXPERIMENTAL
Intervention: Glycyrrhetinic acid (GA) supplementation
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 17272285

Group type: EXPERIMENTAL
Intervention: Community pharmacy-led medicines management intervention
Number of subjects: 1493

Group type: COMPARATOR
Intervention: Control (standard care)
Number of subjects: 1493
Study: 14757388

Group type: EXPERIMENTAL
Intervention: L-alanyl-L-glutamine-supplemented TPN (0.40 g/kg/d)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Standard TPN
Number of subjects: 33
Study: 11159245

Group type: EXPERIMENTAL
Intervention: Nerve blocks (supraorbital and greater occipital)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Subcutaneous infiltration
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Supraorbital nerve blocks
Number of subjects: 20
Study: 9768932

Group type: EXPERIMENTAL
Intervention: Low-dose aprotinin (group A; n = 14)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Low-dose tranexamic acid (group TA; n = 14)
Number of subjects: 42

Group type: COMPARATOR
Intervention: No antifibrinolytics (group C; n = 14)
Number of subjects: 42
Study: 9058145

Group type: EXPERIMENTAL
Intervention: Early enteral nutrition (EEN)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Total parenteral nutrition (TPN)
Number of subjects: 26
Study: 2680271

Group type: EXPERIMENTAL
Intervention: Dietary counseling to reduce calorie intake
Number of subjects: 841

Group type: EXPERIMENTAL
Intervention: Dietary counseling to reduce sodium intake
Number of subjects: 841

Group type: EXPERIMENTAL
Intervention: Dietary counseling to reduce sodium and calorie intake
Number of subjects: 841

Group type: EXPERIMENTAL
Intervention: Dietary counseling to reduce sodium and increase potassium intake
Number of subjects: 841

Group type: COMPARATOR
Intervention: Control group (no dietary counseling)
Number of subjects: 841
Study: 804952

Group type: EXPERIMENTAL
Intervention: Tolamolol 200 mg thrice daily
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: All active treatments (Tolamolol, Propranolol, Practolol)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Propranolol 80 mg thrice daily
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Tolamolol and Propranolol
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Tolamolol (both doses)
Number of subjects: 42
Study: 31464821

Group type: EXPERIMENTAL
Intervention: Online training module
Number of subjects: 74

Group type: COMPARATOR
Intervention: Active control (wait-listed)
Number of subjects: 74
Study: 28202067

Group type: EXPERIMENTAL
Intervention: Acupuncture in addition to standard treatment (N=61 for each study group)
Number of subjects: 488

Group type: COMPARATOR
Intervention: Standard treatment alone (N=61 for each control group)
Number of subjects: 488

Group type: EXPERIMENTAL
Intervention: Acupuncture in addition to standard treatment
Number of subjects: 488

Group type: COMPARATOR
Intervention: Standard treatment alone
Number of subjects: 488
Study: 24959871

Group type: EXPERIMENTAL
Intervention: Kinetic-focused biofeedback
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Kinematic-focused biofeedback
Number of subjects: 4
Study: 24308188

Group type: EXPERIMENTAL
Intervention: ZHUANG medicine mediated thread moxibustion (ZMMTM) combined with Sulfasalazine (SASP)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Sulfasalazine (SASP) alone
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: ZMMTM combined with SASP
Number of subjects: 46
Study: 22119496

Group type: EXPERIMENTAL
Intervention: Everolimus plus octreotide LAR
Number of subjects: 429

Group type: COMPARATOR
Intervention: Placebo plus octreotide LAR
Number of subjects: 429
Study: 19674729

Group type: EXPERIMENTAL
Intervention: Tube group (Baerveldt glaucoma implant)
Number of subjects: 212

Group type: COMPARATOR
Intervention: Trabeculectomy group (mitomycin C 0.4 mg/ml for 4 minutes)
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Tube group
Number of subjects: 212

Group type: COMPARATOR
Intervention: Trabeculectomy group
Number of subjects: 212
Study: 16781075

Group type: EXPERIMENTAL
Intervention: Distraction (movie distraction)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Typical Care
Number of subjects: 136
Study: 15275839

Group type: EXPERIMENTAL
Intervention: Gastrocnemius recession
Number of subjects: 0

Group type: COMPARATOR
Intervention: No intervention (static contractures)
Number of subjects: 0
Study: 11737561

Group type: EXPERIMENTAL
Intervention: Isometric exercise (5 sessions of 1 minute per day for 6 weeks)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control (non-exercise)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Isometric exercise
Number of subjects: 28
Study: 9426083

Group type: EXPERIMENTAL
Intervention: Formoterol 6, 12 and 24 microg
Number of subjects: 28

Group type: COMPARATOR
Intervention: Salmeterol 50 microg
Number of subjects: 28